Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and accounts for more than 90% of primary liver cancer. The advent of immune checkpoint inhibitor (ICI)-related therapies combined with angiogenesis inhibition has revolutionized the treatment of HCC in late-stage and unre...

Full description

Bibliographic Details
Published in:Frontiers in Pharmacology
Main Authors: Jiao Wang, Chengyu Liu, Ronghua Hu, Licheng Wu, Chuanzhou Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Subjects:
HCC
immunotherapy
statins
cholesterol
ICI
inflammation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1324140/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1324140/full

Similar Items